

TRANSCAVAL AORTIC VALVE IMPLANTATION

Mauro De Benedictis



Azienda Ospedaliera Ordine Mauriziano di Torino



Conflict of Interest: None



Alternative Access for TAVI: What we don't know


TURIN

October

24th-26th

2019

• Are the worse outcomes seen with nontransfemoral access related to the underlying morbidities or to the access method itself?







TURIN October 24th-26th 2019

Convertion of trans-thoracic access into more «transfemoral like» procedures should improve outcomes


- Transcaval is transfemoral
- TC only needs conscious sedation
- TC is a transvenous procedure
- Allows rapid ambulation and reduces lengh of stay
- *Proctorship recommended!*





TURIN October 24th-26th 2019

Transcaval Access for TAVI: Reassuring Physiology




- IVC is usually close to aorta without significant intervening structures.
- Interstitial pressure in retroperitonal space is higher than vein.
- Aortic bleeding decompresses through a hole in IVC.






Two New Concepts







TURIN

October

 $24^{\text{th}}\text{-}26^{\text{th}}$

2019

Transcatheter Electrosurgery



31 GIORNATE CARDIOLOGICHE TORINESI

Key elements

Obtain CT-based Treatment Plan

Calcium-free target

Nothing interposed

Away from renal and iliacs

Bailout plan



ID	Type Label	Valu
1	Ellipse Min. Ø	5.5 n
2	Ellipse Min. Ø	10.0



1E 10 LAO 80 RAO L3.1



A	vg. Ø	15.4 mm	bifurcation
100" al: 0°			Target dista
al: 0°	. 12		Endograft b
		0 K (Femoral to
	63	A BAL	Mesenterio
	right R		Caveat & Co
	1E 2E		13-1-

Recommendation (CA-TAVR eligibility)	Favorable; Uncertain; Unfavorable		
Aortic Ca ²⁺ / thickening / ectasia	Aortic calcium grade 2		
Target entry site lumbar vertebra	Mid Body L3 (L3.0)		
Orthogonal projection	Anteroposterior		
Caval-aortic distance X-Y	6 mm		
Interposed structures	none		
Nearby structures	Bowel anterior to target		
Caval lumen diameter	23 mm		
Aortic lumen diameter (+3/0/-1.2cm)	15 mm / 16 mm / 14 mm		
Target distance above aorto-iliac bifurcation	12 mm		
Target distance below R renal artery	75 mm		
Endograft bailout limb access	RCIA 5.2 mm, LCIA 3.0 mm		
Femoral to target centerline distance	24 cm		
Mesenterics	Celiac patent; SMA patent		
Caveat & Comments	15x20 mm target window		


TURIN October 24th-26th 2019



31 GIORNATE CARDIOLOGICHE TORINESI

Aligning, Crossing, Snaring & Advancing





TURIN

October

 $24^{th}-26^{th}$


2019





Closure: Fundamental Pathophysiology Principle

- A venous sink/sump is required to decompress arterial hemorrage
- The hole in IVC must not be occluded unless the hole in the aorta is occluded
- Only withdraw aortic sheath COMPLETELY into cava



TURIN

October

24th-26th


2019



All further remedies are endovascular (\geq 9F)!







TURIN

October

 $24^{\text{th}}\text{-}26^{\text{th}}$

2019

Aortic stent graft





D.E., 81 yo female

STS score morbidity or mortality 20.6 %, mortality 5.5% EUROSCORE II 11.7 %

81 Kg x 156 cm

Cardiovascular risk factors:

Hypertension, diabetes mellitus, dyslipidemia, obesity, OSAS

Comorbidity:

PAD, sideropenic anemia, previous TEA ICA dx. Previous hysterectomy (uterus carcinoma). COPD. CKD (eGFR 35 ml/min/1.73 m2), hip arthrosis.

Cardiological anamnesis:

Known hypertensive cardiopathy Previous hospitalizations for AHF managed with diuretics Worsening NYHA III class Discovery of **severe aortic stenosis** (AVA 0.8 cm2, Gradient max/med 62/42 mmHg). EF 56%




















ID Type Label	Value	25 Type Label	Value
1 Diamatar (Min/Max) Min. Ø	14.6 mm	1 Diameter (MitcMax) Mits E	14.0 mm
Mun. O	15.5 mm	Max. D	TAJImm
Aug. 0	12.5 mm	Avg. 0	54.1 mm